<DOC>
	<DOC>NCT02673489</DOC>
	<brief_summary>The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.</brief_summary>
	<brief_title>A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com Genotype 3 HCV HCV RNA â‰¥10000 IU (International Unit)/mL Compensated Liver Cirrhosis BMI 1840 kg/m2 Previously treated for HCV or never treated for HCV Infection with HCV other than Genotype 3. Mixed infection of any genotype Evidence of decompensated liver disease Previous exposure to NS5A inhibitors Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>